Psilocybin is a naturally occurring compound found in certain mushroom species that acts as a powerful stimulator of serotonin receptors in the brain. Once ingested, it’s rapidly converted into an active form called psilocin, which triggers a cascade of changes in brain chemistry, perception, and neural connectivity that can last four to six hours. These effects range from visual distortions and altered sense of self to measurable shifts in how brain networks communicate, and they’re now being studied as a potential treatment for depression and other mental health conditions.
How Psilocybin Works in the Brain
Psilocybin itself is actually a prodrug, meaning your body has to convert it before it becomes active. Enzymes in your gut and liver strip off a phosphate group, turning psilocybin into psilocin. This conversion happens quickly, and psilocin then crosses into the brain where it binds primarily to a specific type of serotonin receptor called 5-HT2A. This receptor is the main driver of the psychedelic experience. Psilocin also has weaker activity at a few other serotonin receptor subtypes, but blocking studies in humans confirm that the 5-HT2A receptor is responsible for the core psychological effects.
Once psilocin activates these receptors, the brain’s normal communication patterns shift dramatically. One of the most consistent findings in brain imaging research is that psilocybin decreases activity within the default mode network (DMN), a set of brain regions that’s most active during self-referential thinking, mind-wandering, and maintaining your sense of identity. Normally, the front and back hubs of this network fire in tight coordination. Under psilocybin, they decouple, and the usual boundaries between brain networks start to dissolve. Regions that don’t typically talk to each other begin exchanging signals. The brain shifts from a modular, compartmentalized state to something more globally interconnected.
This rewiring of communication patterns is thought to underlie many of the subjective effects people report: the blurring of boundaries between self and surroundings, the sense that familiar thoughts and perceptions are being experienced from an entirely new angle, and the emotional intensity that often accompanies a psilocybin experience.
What the Experience Feels Like
Effects typically become noticeable 30 to 60 minutes after an oral dose, peak around two to three hours in, and fade to negligible levels by about six hours. The intensity depends heavily on dose. In clinical studies, participants rate the subjective intensity of a low dose at roughly 0.51 on a 0-to-1 scale, compared to 0.75 for a high dose.
At lower doses, people commonly notice enhanced colors, geometric patterns with eyes closed, shifts in emotional tone, and a heightened sense of meaning or significance in ordinary things. At higher doses, the experience deepens considerably. Visual distortions become more pronounced, time perception warps, and many people report what researchers call “oceanic boundlessness,” a dissolution of the normal sense of where you end and the world begins. This ego dissolution can feel profoundly meaningful or deeply unsettling depending on the person and the setting. Some people experience anxiety, confusion, or paranoia, particularly during the come-up phase before the peak.
Physical Effects on the Body
Psilocybin produces modest, temporary increases in heart rate and blood pressure. Across multiple clinical trials, peak systolic blood pressure typically rises to somewhere between 120 and 155 mmHg, with higher doses pushing higher. Heart rate generally climbs into the 75 to 95 beats-per-minute range. These changes are dose-dependent and resolve on their own without medical intervention.
That said, a meaningful percentage of people in clinical studies do hit notable blood pressure spikes. In one high-dose study, 34% of participants experienced a systolic reading above 160 mmHg, and 13% had a diastolic reading above 100. For most healthy adults, these transient spikes aren’t dangerous, but they’re relevant for anyone with cardiovascular concerns. Other common physical effects include nausea (especially during onset), dilated pupils, and mild changes in body temperature.
How Quickly It’s Metabolized
Psilocin has a relatively short half-life, ranging from about 1.5 to 4.8 hours depending on the study and the individual. The body clears it through several enzyme pathways in the liver. This rapid metabolism is one reason the total experience is relatively brief compared to other psychedelics. By the time six hours have passed, psilocin levels in the blood have dropped substantially, and most people feel functionally back to baseline within that window, though some residual emotional or perceptual shifts can linger into the following day.
Changes to Brain Structure
One of the more striking findings in recent research is that psilocybin appears to promote physical changes in brain cells. A study using in-vivo imaging in mice found that a single dose led to roughly a 10% increase in the size and density of dendritic spines, the tiny protrusions on neurons where synaptic connections form. These structural changes appeared within 24 hours and were still present a month later, with about a third of the newly formed spines persisting at the 34-day mark.
This rapid synapse growth in the frontal cortex is notable because depression and chronic stress are associated with a loss of these same synaptic connections. The fact that psilocybin can trigger new spine formation quickly, and that a significant fraction of those new connections stick around, offers a plausible biological explanation for why a single psilocybin session might produce lasting changes in mood and cognitive flexibility. Changes in brain network modularity observed one day after psilocybin administration in depressed patients have been linked to better clinical outcomes six months later.
Psilocybin for Depression
The clinical trial results for depression have been unusually strong for a psychiatric treatment, though the research is still in relatively early stages. In a 2022 follow-up study of people with major depressive disorder, 75% still met criteria for treatment response at 12 months, and 58% were in full remission. A head-to-head trial comparing psilocybin to escitalopram (a standard antidepressant) found that 57% of the psilocybin group achieved remission at six weeks, compared to 28% in the escitalopram group. Studies in people with cancer-related depression and anxiety have shown clinically significant symptom reductions in 60 to 80% of participants, with improvements lasting more than six months.
For treatment-resistant depression, an early open-label trial found that 67% of patients reached remission one week after treatment, though that number dropped to 42% at three months. These are small studies, and the open-label design of several trials means placebo effects and expectancy could inflate the numbers. Still, the consistency of large effect sizes across different research groups and patient populations has generated serious clinical interest.
Where Things Stand Legally and Medically
The FDA granted psilocybin breakthrough therapy designation for treatment-resistant depression in 2018 and for major depressive disorder in 2019. This designation is meant to speed up the review process for drugs that show substantial improvement over existing treatments. Despite this, psilocybin has no FDA approval as of now. Only three advanced trials (Phase 2/3 or Phase 3) have been submitted, all within the last two years, and optimistic estimates put a possible approval at roughly three to four years out, assuming positive results and no regulatory delays. There are currently 134 registered clinical trials studying psilocybin across more than 50 potential uses.
Psilocybin remains a Schedule I controlled substance at the federal level in the United States, though Oregon and Colorado have created regulated frameworks for supervised use. Several cities have deprioritized enforcement of psilocybin possession laws.
Risks and Adverse Effects
The most common acute risk is psychological distress during the experience itself, sometimes called a “bad trip.” This can involve intense fear, paranoia, confusion, or disturbing visual imagery. In supervised clinical settings with trained guides and careful screening, these episodes are generally manageable and don’t result in lasting harm. Outside controlled settings, the risks increase significantly, particularly for people with a personal or family history of psychotic disorders like schizophrenia, where psilocybin could potentially trigger a psychotic episode.
A small number of people develop persistent visual disturbances after using psychedelics, a condition called hallucinogen persisting perception disorder (HPPD). The prevalence is thought to be low, but reliable estimates don’t exist because epidemiological data is scarce and many people never seek treatment. HPPD involves ongoing visual phenomena like halos, trailing images, or geometric patterns that persist long after the drug has left the body. It’s not well understood which individuals are susceptible or why it occurs in some people and not others.